^
    Apply
    Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients (NCT02987829)
    Phase 1/2
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    04/23/2021
    Initiation :
    05/23/2017
    Primary completion :
    10/06/2019
    Completion :
    11/09/2020
    AR
    |
    TRC253